Cargando…
Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
Macular edema (ME) is associated with various conditions; however, the main causes of ME are retinal vein occlusion (RVO) and diabetes. Laser photocoagulation, formerly the gold standard for the treatment of ME, has been replaced by anti-vascular endothelial growth factor (anti-VEGF) intravitreal in...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619917/ https://www.ncbi.nlm.nih.gov/pubmed/34830582 http://dx.doi.org/10.3390/jcm10225300 |
_version_ | 1784605100286672896 |
---|---|
author | Grzybowski, Andrzej Markeviciute, Agne Zemaitiene, Reda |
author_facet | Grzybowski, Andrzej Markeviciute, Agne Zemaitiene, Reda |
author_sort | Grzybowski, Andrzej |
collection | PubMed |
description | Macular edema (ME) is associated with various conditions; however, the main causes of ME are retinal vein occlusion (RVO) and diabetes. Laser photocoagulation, formerly the gold standard for the treatment of ME, has been replaced by anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections. Despite its efficiency, this treatment requires frequent injections to preserve the outcomes of anti-VEGF therapy, and as many patients do not sufficiently respond to the treatment, ME is typically a chronic condition that can lead to permanent visual impairment. Generalized recommendations for the treatment of ME are lacking, which highlights the importance of reviewing treatment approaches, including recent anti-VEGFs, intravitreal steroid implants, and subthreshold micropulse lasers. We reviewed relevant studies, emphasizing the articles published between 2019 and 2021 and using the following keywords: macular edema, diabetic macular edema, retinal vein occlusion, laser photocoagulation, anti-VEGF, and intravitreal injections. Our results revealed that a combination of different treatment methods may be beneficial in resistant cases. Additionally, artificial intelligence (AI) is likely to help select the best treatment option for patients in the near future. |
format | Online Article Text |
id | pubmed-8619917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86199172021-11-27 Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update Grzybowski, Andrzej Markeviciute, Agne Zemaitiene, Reda J Clin Med Review Macular edema (ME) is associated with various conditions; however, the main causes of ME are retinal vein occlusion (RVO) and diabetes. Laser photocoagulation, formerly the gold standard for the treatment of ME, has been replaced by anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections. Despite its efficiency, this treatment requires frequent injections to preserve the outcomes of anti-VEGF therapy, and as many patients do not sufficiently respond to the treatment, ME is typically a chronic condition that can lead to permanent visual impairment. Generalized recommendations for the treatment of ME are lacking, which highlights the importance of reviewing treatment approaches, including recent anti-VEGFs, intravitreal steroid implants, and subthreshold micropulse lasers. We reviewed relevant studies, emphasizing the articles published between 2019 and 2021 and using the following keywords: macular edema, diabetic macular edema, retinal vein occlusion, laser photocoagulation, anti-VEGF, and intravitreal injections. Our results revealed that a combination of different treatment methods may be beneficial in resistant cases. Additionally, artificial intelligence (AI) is likely to help select the best treatment option for patients in the near future. MDPI 2021-11-15 /pmc/articles/PMC8619917/ /pubmed/34830582 http://dx.doi.org/10.3390/jcm10225300 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Grzybowski, Andrzej Markeviciute, Agne Zemaitiene, Reda Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update |
title | Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update |
title_full | Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update |
title_fullStr | Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update |
title_full_unstemmed | Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update |
title_short | Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update |
title_sort | treatment of macular edema in vascular retinal diseases: a 2021 update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619917/ https://www.ncbi.nlm.nih.gov/pubmed/34830582 http://dx.doi.org/10.3390/jcm10225300 |
work_keys_str_mv | AT grzybowskiandrzej treatmentofmacularedemainvascularretinaldiseasesa2021update AT markeviciuteagne treatmentofmacularedemainvascularretinaldiseasesa2021update AT zemaitienereda treatmentofmacularedemainvascularretinaldiseasesa2021update |